Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families

Cancer Genetics and Cytogenetics

Volumn 169, Issue 1, 2006, Pages 62-68

  Maillet, Philippe ^a   Chappuis, Pierre Olivier ^a   Khoshbeen Boudal, Mary ^a   Sciretta, Véronique ^a   Sappino, André Pascal ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA POLYMORPHISM; FEMALE; FRAMESHIFT MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; OVARIAN NEOPLASMS;

EID: 33746216897     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.03.010     Document Type: Article

References (21)

1. Easton D., Ford D., and Peto J. Inherited susceptibility to breast cancer. Cancer Surv 18 (1993) 95-113
2. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., Timmerman M.M., Brody L.C., and Tucker M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997) 1401-1408
3. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A., Gayther S.A., Zelada-Hedman M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62 (1998) 676-689
4. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., and Easton D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130 [Erratum in: Am J Hum Genet 2003;73:709]
5. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
6. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 (2004) 665-676
7. Goldgar D.E., Easton D.F., Deffenbaugh A.M., Monteiro A.N., Tavtigian S.V., and Couch F.J. Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75 (2004) 535-544
8. Rebbeck T.R., Spitz M., and Wu X. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5 (2004) 589-597
9. Hampel H., Sweet K., Westman J.A., Offit K., and Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 41 (2004) 81-91
10. Parmigiani G., Berry D., and Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 (1998) 145-158
11. Pichert G., and Stahel R.A. Organizing cancer genetics programs: the Swiss model. J Clin Oncol 18 21 Suppl (2000) 65S-69S
12. Antonarakis S.E. Nomenclature Working Group. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 11 (1998) 1-3
13. Sunyaev S., Ramensky V., Koch I., Lathe III W., Kondrashov A.S., and Bork P. Prediction of deleterious human alleles. Hum Mol Genet 10 (2001) 591-597
14. Bochar D.A., Wang L., Beniya H., Kinev A., Xue Y., Lane W.S., Wang W., Kashanchi F., and Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102 (2000) 257-265
15. Vallon-Christersson J., Cayanan C., Haraldsson K., Loman N., Bergthorsson J.T., Brondum-Nielsen K., Gerdes A.M., Moller P., Kristoffersson U., Olsson H., Borg A., and Monteiro A.N. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10 (2001) 353-360
16. Mirkovic N., Marti-Renom M.A., Weber B.L., Sali A., and Monteiro A.N. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64 (2004) 3790-3797
17. Williams R.S., Lee M.S., Hau D.D., and Glover J.N. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11 (2004) 519-525
18. Fleming M.A., Potter J.D., Ramirez C.J., Ostrander G.K., and Ostrander E.A. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A 100 (2003) 1151-1156
19. Abkevich V., Zharkikh A., Deffenbaugh A.M., Frank D., Chen Y., Shattuck D., Skolnick M.H., Gutin A., and Tavtigian S.V. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41 (2004) 492-507
20. Claes K., Poppe B., Machackova E., Coene I., Foretova L., De Paepe A., and Messiaen L. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 37 (2003) 314-320
21. Chenevix-Trench G., Healey S., Lakhani S., Waring P., Cummings M., Brinkworth R., Deffenbaugh A.M., Burbidge L.A., Pruss D., Judkins T., Scholl T., Bekessy A., Marsh A., Lovelock P., Wong M., Tesoriero A., Renard H., Southey M., Hopper J.L., Yannoukakos K., Brown M., Easton D., Tavtigian S.V., Goldgar D., Spurdle A.B., and kConFab Investigators. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66 (2006) 2019-2027